FDA Halts Multiple Cell Therapy Trials Following Patient Deaths.

Ar­cel­lx's CAR-modified T cell therapy trial for multiple myeloma has been put on hold after a patient died. The therapy is the company's lead program and part of Gilead's efforts to commercialize additional cell therapies. Gilead contributed $225 million upfront on the program last year.